Impact of the Extent of Coronary Artery Disease on Outcomes After Revascularization for Unprotected Left Main Coronary Artery Stenosis  by Kim, Young-Hak et al.
R
t
i
b
c
s
r
i
s
F
M
M
a
(
b
Journal of the American College of Cardiology Vol. 55, No. 23, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PImpact of the Extent of Coronary Artery Disease
on Outcomes After Revascularization for
Unprotected Left Main Coronary Artery Stenosis
Young-Hak Kim, MD, PHD,* Duk-Woo Park, MD, PHD,* Won-Jang Kim, MD,*
Jong-Young Lee, MD,* Sung-Cheol Yun, PHD,† Soo-Jin Kang, MD, PHD,*
Seung-Whan Lee, MD, PHD,* Cheol Whan Lee, MD, PHD,* Myeong-Ki Hong, MD, PHD,*
Seong-Wook Park, MD, PHD,* Seung-Jung Park, MD, PHD*
Seoul, Korea
Objectives This study was designed to examine the impact of the extent of coronary disease on long-term outcomes af-
ter coronary stenting or coronary artery bypass graft (CABG) surgery for unprotected left main coronary ar-
tery (ULMCA) stenosis.
Background The differential outcome of ULMCA revascularization according to the coronary involvement remains uncertain.
Methods From the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of
Percutaneous Coronary Angioplasty versus Surgical Revascularization) registry, 2,240 patients with ULMCA ste-
nosis who underwent either stenting or CABG were stratified by number of diseased vessels.
Results Following adjustment with EuroSCORE (European System for Cardiac Operative Risk Evaluation), diabetes melli-
tus, and bifurcation stenosis, stents and CABG had similar risks of death and major adverse cardiac events in-
cluding death, Q-wave myocardial infarction, or stroke in all subgroups regardless of the number of diseased
vessels over 4 years. In patients with 2-vessel (23.0% vs. 14.2%; hazard ratio [HR]: 1.739; 95% confidence inter-
val [CI]: 1.171 to 2.582; p  0.006) or 3-vessel (25.0% vs. 17.6%; HR: 1.493; 95% CI: 1.096 to 2.035; p 
0.011) disease, however, stenting was associated with a higher risk of major adverse cardiac and cerebrovascu-
lar events including major adverse cardiac events or target vessel revascularization than CABG. Interaction of
vascular involvement with type of stent or CABG was not significant.
Conclusions Stenting appears to be a safe alternative to CABG in patients having ULMCA stenosis combined with additional
vascular disease. The advantage of CABG over stenting lies principally in the reduction of repeat revasculariza-
tion across subgroups stratified by the number of diseased vessels. (J Am Coll Cardiol 2010;55:2544–52)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.094d
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decent clinical studies have compared the initial and long-
erm safety and effectiveness of percutaneous coronary
ntervention with coronary artery stents with coronary artery
ypass graft (CABG) surgery for unprotected left main
oronary artery (ULMCA) stenosis (1–7). Despite coronary
tenting showing an increased tendency of target vessel
evascularization (TVR), the long-term outcomes of stent-
ng, either with bare-metal stents (BMS) or drug-eluting
tents (DES), were comparable to those of CABG, as
rom the *Departments of Cardiology and †Division of Biostatistics, Center for
edical Research and Information, University of Ulsan College of Medicine, Asan
edical Center, Seoul, Korea. Supported by a grant of the Korea Health 21 Research
nd Development Project, Ministry of Health and Welfare, Republic of Korea
A090264).p
Manuscript received July 16, 2009; revised November 25, 2009, accepted Novem-
er 30, 2009.etermined by the occurrence of major adverse cardiac or
erebrovascular events (MACCE). Due to a lack of statis-
ical power, however, the differential outcomes of stents
ersus CABG in subgroups stratified by the presence of
omorbidities related to poor prognosis remain uncertain. In
act, although the extent of extra-ULMCA coronary dis-
ase, represented by the number of diseased vessels, has
een considered a risk factor predicting adverse outcomes,
o study has specifically addressed this issue (8–12). A
See page 2553
ecent subgroup analysis of the SYNTAX (Synergy between
ercutaneous Coronary Intervention with Taxus and Car-
iac Surgery) randomized trial suggested that DES ap-
eared to be comparable to CABG for patients with
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ivessel ULMCA stenosis in terms of the risk of MACCE
13). This study, however, had inherent limitations associated
ith subgroup analyses, in which the probability of false
ositive might be increased by the multiplicity issue (14).
We have therefore assessed the impact of extra-ULMCA
ascular disease on long-term outcomes in revasculariza-
ion for ULMCA stenosis in patients enrolled in the
AIN-COMPARE (Revascularization for Unprotected
eft MAIN Coronary Artery Stenosis: Comparison of
ercutaneous Coronary Angioplasty versus Surgical Revas-
ularization) registry. The MAIN-COMPARE registry
ad shown comparable 3-year risks of death or myocardial
nfarction and higher risks of TVR with stenting than with
ABG in the overall population (5). In this substudy, we
xtended the follow-up duration to 4 years and compared
he outcomes of stenting versus CABG in patients stratified
ccording to the extent of coronary artery disease.
ethods
ubjects. The MAIN-COMPARE study enrolled patients
ith ULMCA stenosis who underwent either CABG or
tenting as the index procedure at 12 major cardiac centers
n Korea between January 2000 and June 2006 (5). The left
ain coronary artery was considered unprotected if there
ere no patent grafts to the left anterior descending artery
r circumflex artery. Patients who had undergone previous
ABG, those who underwent concomitant valvular or
ortic surgery, and those who had ST-segment elevation
yocardial infarction or presented with cardiogenic shock
ere excluded. The local ethics committee at each hospital
pproved the use of clinical data for this study, and all
atients provided written informed consent.
rocedures. In the institutions involved in this study,
ABG has been formally recommended as the standard
herapy for patients having ULMCA stenosis. On the other
and, stenting for such a lesion was performed according to
he preference of the patient or physician, as well as in
atients with high risks associated with CABG, when the
atients had suitable coronary anatomy for stenting. From
anuary 2000 through May 2003, all coronary stenting was
erformed with BMS, whereas from May 2003 through
une 2006, stenting was exclusively performed with DES.
or DES, sirolimus-eluting stents (Cypher, Cordis Corpo-
ation, Miami Lakes, Florida) or paclitaxel-eluting stents
Taxus, Boston Scientific, Natick, Massachusetts) were
elected at the discretion of the operator. Procedures for
LMCA and other vessels were performed using standard
nterventional techniques. All patients undergoing stenting
ere prescribed aspirin plus clopidogrel (loading dose: 300
r 600 mg) or ticlopidine (loading dose: 500 mg) before or
uring the procedure, and aspirin was continued indefinitely
fter the procedure. Patients treated with BMS were pre-
cribed clopidogrel or ticlopidine for at least 1 month, and
atients treated with DES were prescribed clopidogrel for at weast 6 months. Surgical revascu-
arization was performed using
tandard bypass techniques. When-
ver possible, the internal tho-
acic artery was used preferen-
ially for revascularization of the
eft anterior descending artery.
ollow-up and end points.
linical, angiographic, procedural,
nd outcome data were collected
sing a dedicated Internet-based
eporting system. All outcomes of
nterest were adjudicated by the
entral events committee. In addi-
ion, information about vital status
as ascertained from the National
opulation Registry of the Korea
ational Statistical Office. Clinical
ollow-up was recommended at 1
onth, 6 months, 1 year, and annually thereafter. Routine
ngiographic follow-up for all patients treated with stenting
as recommended at 6 to 10 months after the procedure.
owever, for patients who underwent CABG, angiographic
ollow-up was recommended only if there were ischemic
ymptoms or signs during follow-up.
The primary end point of the study was the major adverse
ardiac events (MACE), defined as the composite of death,
-wave myocardial infarction, or stroke. The other out-
omes such as death, stroke, TVR, or MACCE including
ACE or TVR were considered as secondary end points.
eath was defined as death from any cause. Q-wave
yocardial infarction was defined as documentation of a
ew abnormal Q-wave after the index treatment. Stroke, as
ndicated by neurologic deficits, was confirmed by a neurol-
gist on the basis of imaging analyses. Target lesion revas-
ularization (TLR) was defined as any repeat revasculariza-
ion with percutaneous coronary intervention or CABG
urgery in the target ULMCA or within the adjacent 5 mm.
VR was defined as repeat revascularization of the treated
LMCA, including any segments of the left anterior
escending artery, left circumflex artery, or ULMCA.
xtra-ULMCA extent and elsewhere of coronary disease
as defined as the presence of significant narrowing (50%
iameter stenosis) in a major epicardial vessel, including the
eft anterior descending artery, left circumflex artery, and
ight coronary artery. Ostial stenosis of the left anterior
escending artery or circumflex artery was regarded as part
f the bifurcation ULMCA stenosis and was therefore not
onsidered as extra-ULMCA extent.
To compare angiographic complexity in both treatment
roups, the SYNTAX scores were retrospectively calculated
or 1,580 (70.5%) patients from the overall cohort at the
ngiographic Core Laboratory in CardioVascular Research
oundation, Seoul, Korea, according to the algorithm (8).
tatistical analysis. The main purpose of this study, which
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
DES  drug-eluting stent(s)
MACCE  major adverse
cardiac and
cerebrovascular events
MACE  major adverse
cardiac events
TLR  target lesion
revascularization
TVR  target vessel
revascularization
ULMCA  unprotected left
main coronary arteryas pre-specified in the initial protocol, was to compare the
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Left Main With Multivessel Disease June 8, 2010:2544–52ncidence of outcomes following stenting versus CABG in
atients stratified by the extra-ULMCA extent and else-
here of coronary artery disease. In addition, to identify the
mpact of stent design on clinical outcomes, comparisons
etween stent versus CABG were stratified into the first
ave (Wave #1), comparing BMS and contemporary
ABG, and the second wave (Wave #2), comparing DES
nd contemporary CABG, as described (5). We also as-
essed the impact of extra-ULMCA coronary artery disease
n outcomes within each treatment strategy.
Baseline demographic, clinical, and angiographic charac-
eristics were reported as median and interquartile range
IQR) for continuous variables and number and percentage
or categorical variables. Continuous variables were com-
ared using the Mann-Whitney U test for 2 groups and the
ruskal-Wallis test for multiple groups. Categorical vari-
bles were compared using the chi-square test or Fisher
xact test, when appropriate. Unadjusted cumulative inci-
ences of events were analyzed using Kaplan-Meier meth-
ds and compared using the log-rank test. All patients were
ensored at the time of an event or at a fixed interval of 4
ears. When the cumulative incidence of composite out-
omes was analyzed, the patient was censored at the first
vent. Hazard ratios (HRs) and 95% confidence intervals
CIs) were calculated with Cox proportional hazard models.
ue to the limited number of events in each subgroup,
djustment was performed using 3 fixed covariates including
he standard EuroSCORE (European System for Cardiac
perative Risk Evaluation), the presence of diabetes melli-
us, and bifurcation ULMCA involvement, which were
raditionally considered as important risk factors of revas-
ularization therapy for ULMCA disease (15–17). In addi-
ion, an accessory Cox model was also created to adjust
ngiographic complexity using the SYNTAX score and
uroSCORE without imputation method. Interactions be-
ween factors associated with the extent of coronary artery
isease and treatment strategy were tested by incorporation
f formal interaction terms in the multivariable Cox model.
All reported p values are 2-sided, and p  0.05 was
onsidered statistically significant. SPSS software version 11
SPSS Inc., Chicago, Illinois) was used for all statistical
nalyses.
esults
atient characteristics. A total of 2,240 patients were
ncluded in our analysis; their demographic, clinical, and
ngiographic characteristics are listed in Table 1. Within
ither the stent or the CABG group, patients having
ultivessel disease plus ULMCA stenosis were likely to be
lder; have a greater prevalence of diabetes mellitus, hyper-
ension, hyperlipidemia, cerebrovascular disease, bifurcation
LMCA involvement, and right coronary artery stenosis;
nd have lower left ventricular ejection fraction and higher
uroSCORE than patients having isolated ULMCA or
-vessel disease. Compared with patients undergoing 2ABG, those undergoing stenting had a higher prevalence
f prior percutaneous coronary intervention, less involve-
ent of bifurcation ULMCA and right coronary artery
tenosis, and lower ejection fraction; this was particularly
rue in subgroups having multivessel disease. The SYNTAX
core was significantly higher with extensive coronary artery
nvolvement in either stent or CABG groups. In addition,
he score was higher in patients undergoing CABG than
hose undergoing stenting in all subgroups.
nadjusted event rate at 4 years. When the follow-up was
ensored at 4 years, the mean duration of follow-up was
5.4 months (IQR 38.8 to 48.0 months) in the stent group
nd 48.0 months (IQR 44.8 to 48.0 months) in the CABG
roup (p  0.001). In the stent group, patients receiving
MS were followed for the median of 48.0 months (IQR
6.7 to 48.0 months) and those receiving DES for 42.8
onths (IQR 38.2 to 48.0 months) (p  0.001).
The observed incidences of unadjusted outcomes are
isted in Table 2. Figure 1 shows the Kaplan-Meier inci-
ences of MACE and MACCE in the subgroups. For all
ubgroups, the incidence of death, stroke, or MACE did
ot differ between the stent and CABG groups. Among the
ubgroups with 2- or 3-vessel plus ULMCA disease, how-
ver, the incidence of MACCE was significantly higher in
he stent group than in the CABG group, which was driven
y increased incidence of TVR. The difference of TLR or
VR rates between the stent and CABG groups was
onsistently observed in patients with isolated ULMCA; 1-,
-, or 3-vessel disease in the overall patients; and in Wave
1 including patients receiving BMS. However, in Wave
2, including patients receiving DES, TLR or TVR did not
tatistically differ between the stent and CABG groups.
mong the subgroups with isolated ULMCA stenosis or
-vessel plus ULMCA disease, the incidence of MACCE
id not statistically differ between the stent and CABG
roups. However, in patients with 2- or 3-vessel plus
LMCA disease, the MACCE rate was higher in the stent
roup than in the CABG group in either Waves #1 or #2.
he Kaplan-Meier incidence of revascularization for extra-
LMCA coronary artery disease, between the stent and
ABG groups, was 1.0% versus 0% (p  0.435) in isolated
LMCA, 3.2% versus 1.8% (p  0.485) in 1-vessel, 5.5%
ersus 2.1% (p  0.040) in 2-vessel, and 4.6% versus 2.9%
p  0.086) in 3-vessel plus ULMCA stenoses. At 4 years,
ngiographic stent thrombosis occurred in 11 patients
1.5  0.4%) receiving DES and 1 patient (0.7  0.3%)
eceiving BMS (log-rank p  0.120).
There was a difference in the impact of extra-ULMCA
oronary disease involvement on long-term outcomes be-
ween the 2 treatment strategies. In the CABG group, the
ncidence of MACE or MACCE did not statistically differ
etween patients with isolated ULMCA disease and those
ith 1-, 2-, or 3-vessel disease. Similarly, in the stent group,
he incidences of composite outcomes did not differ between
atients with isolated ULMCA disease and those with 1- or
-vessel disease. However, the incidences of MACE (12.9%
Baseline Characteristics of the PatientsTable 1 Baseline Characteristics of the Patients
Variable
Isolated LM LM With 1 Vessel LM With 2 Vessels LM With 3 Vessels p Value
in Stent
Group*
p Value
in CABG
Group*Stent CABG p Value Stent CABG p Value Stent CABG p Value Stent CABG p Value
Patients, n 278 71 264 119 287 299 273 649
Age, yrs 55 (47–64) 55 (48–63) 0.47 60 (52–67) 63 (56–71) 0.11 64 (55–71) 64 (57–69) 0.21 68 (61–74) 65 (59–71) 0.001 0.001 0.001
Male sex, % 61.5 69 0.24 75.4 68.9 0.19 72.8 76.6 0.29 73.3 72.4 0.79 0.001 0.30
Diabetes mellitus
Any diabetes 20.1 18.3 0.73 27.7 25.2 0.62 35.5 30.8 0.22 35.2 40.1 0.16 0.001 0.001
Requiring insulin 2.5 7.0 0.06 6.8 10.1 0.27 9.4 6.4 0.17 8.4 8.8 0.86 0.007 0.51
Hypertension 37.1 31.0 0.34 47.7 42.9 0.38 55.1 50.2 0.24 58.2 52.2 0.10 0.001 0.003
Hyperlipidemia 20.9 19.7 0.83 25.0 28.6 0.46 33.1 28.1 0.19 35.5 36.8 0.71 0.001 0.003
Current smoker 18.0 26.8 0.10 21.6 27.7 0.19 21.6 26.1 0.20 24.5 20.6 0.19 0.32 0.13
Prior angioplasty 9.7 9.9 0.97 18.2 12.6 0.17 22.6 13.0 0.002 22.0 9.9 0.001 0.001 0.47
Prior myocardial infarction 2.5 4.2 0.44 9.5 5.9 0.24 11.5 11.4 0.96 8.8 13.6 0.043 0.001 0.019
Prior heart failure 1.4 4.2 0.15 1.9 2.5 0.71 2.1 1.3 0.54 4.4 4.3 0.96 0.11 0.08
Chronic pulmonary disease 2.5 0 0.35 2.3 2.5 1.00 1.0 3.0 0.09 2.2 1.7 0.79 0.60 0.34
Cerebrovascular disease 3.2 1.4 0.69 6.8 2.5 0.09 8.4 7.0 0.54 9.9 8.9 0.65 0.02 0.016
Peripheral vascular disease 0.4 2.8 0.11 0.8 5.0 0.013 1.0 5.4 0.003 3.7 5.9 0.17 0.01 0.84
Renal failure 0.4 2.8 0.11 0.4 4.2 0.012 4.9 3.3 0.35 5.1 2.6 0.054 0.001 0.69
Ejection fraction, % 64 (59–68) 64 (59–67) 0.79 62 (57–68) 63 (58–67) 0.60 62 (57–68) 61 (54–66) 0.049 60 (54–65) 58 (48–64) 0.001 0.001 0.001
EuroSCORE 3.0 (2.0–4.3) 3.0 (2.0–5.0) 0.16 3.0 (2.0–5.0) 4.0 (3.0–6.0) 0.001 4.0 (2.0–5.0) 4.0 (3.0–6.0) 0.17 4.0 (3.0–6.0) 5.0 (3.0–6.0) 0.17 0.001 0.001
SYNTAX score 13 (11–16) 17 (13–25) 0.001 20 (14–27) 28 (21–34) 0.001 27 (20–33) 33 (27–41) 0.001 31 (23–38) 42 (34–52) 0.001 0.001 0.001
Atrial fibrillation 1.4 5.6 0.06 2.7 2.5 1.00 1.7 2.3 0.61 2.2 2.6 0.71 0.76 0.46
Clinical indication, % 0.29 0.14 0.007 0.001 0.12 0.11
Silent ischemia 2.5 2.6 2.3 1.7 4.2 2.3 2.9 1.8
Stable angina 32.7 23.9 36.0 26.1 30.3 20.7 29.3 17.9
Unstable angina 58.6 63.4 52.7 65.5 55.4 69.2 53.8 68.6
NSTEMI 6.1 7.0 9.1 6.7 10.1 7.7 13.9 11.7
Bifurcation LM stenosis 21.7 33.8 0.037 49.4 53.0 0.52 64.0 54.0 0.018 63.5 51.7 0.001 0.001 0.025
Right coronary disease 0.7 0 1.00 15.2 26.9 0.007 33.8 46.5 0.002 94.1 97.5 0.01 0.001 0.001
Restenotic lesion 2.9 5.6 0.27 3.8 1.7 0.36 3.8 1.7 0.11 1.1 0.5 0.37 0.19 0.004
The values are presented with median (interquartile range) and number (percentage). *The p values among 4 groups stratified by extra left main coronary artery involvement within the stenting or CABG group.
CABG  coronary artery bypass grafting; EuroSCORE  European System for Cardiac Operative Risk Evaluation; LM  left main; NSTEMI  non–ST-segment elevation myocardial infarction; SYNTAX  Synergy between Percutaneous Coronary Intervention with Taxus and
Cardiac Surgery.
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Left Main With Multivessel Disease June 8, 2010:2544–52s. 5.5%, p  0.003) or MACCE (25.0% vs. 17.0%, p 
.016) were significantly higher in patients with 3-vessel
lus ULMCA disease than in those with isolated ULMCA
isease.
djusted HRs. IMPACT OF VASCULAR DISEASE. After ad-
usting for differences in EuroSCORE, diabetes mellitus,
nd bifurcation ULMCA stenosis, the risks of death,
ACE, or MACCE were not associated with the number
f extra-ULMCA coronary artery disease in either stent or
ABG groups (Fig. 2). Similarly, when the patients receiv-
ng stents were separated into those receiving DES and
MS, risk of MACE or MACCE was not associated with
he number of diseased vessels.
TENT VERSUS CABG ACCORDING TO VASCULAR DISEASE.
igure 3 shows the HRs and CIs of outcomes following
he use of stents or CABG in patient subgroups stratified
y the number of extra-ULMCA coronary artery disease.
tenting and CABG showed comparable risks of death
nd MACE across subgroups stratified by vascular dis-
ase, both for the overall patient population and for
aves #1 and #2. However, the risk of MACCE was
aplan-Meier Cumulative Incidence of Adverse Outcomes at 4 YearTable 2 Kaplan-Meier Cumulative Incidence of Adverse Outcom
Outcomes
Isolated LM LM With 1 Ves
Stent CABG
Log-Rank
p Value Stent CABG
Overall patients
Patients, n 278 71 264 119
Death 4.4 5.6 0.631 8.6 5.9
Q-wave MI 0.4 1.5 0.290 0.4 0.8
Stroke 1.1 1.4 0.796 1.2 1.8
MACE 5.5 7.0 0.575 8.6 8.4
TLR at LM 11.3 1.5 0.014 5.1 1.7
TVR 12.3 1.5 0.009 8.2 2.6
MACCE 17.0 8.5 0.094 15.7 10.1
Wave #1*
Patients, n 133 45 82 65
Death 7.7 4.4 0.488 6.3 4.6
Q-wave MI 0.8 0 0.564 1.2 1.5
Stroke 0 2.3 0.079 0 3.2
MACE 7.7 6.7 0.876 6.3 9.2
TLR at LM 16.0 2.3 0.020 10.0 1.6
TVR 16.0 2.3 0.020 12.7 3.1
MACCE 22.0 8.9 0.066 17.4 10.8
Wave #2*
Patients, n 145 26 182 54
Death 1.4 7.7 0.046 9.4 7.4
Q-wave MI 0 4.0 0.016 0 0
Stroke 2.1 0 0.475 1.8 0
MACE 3.5 7.7 0.297 9.4 7.4
TLR at LM 6.9 0 0.185 2.9 1.9
TVR 9.4 0 0.129 6.1 1.9
MACCE 12.8 7.7 0.525 14.7 9.3
In Wave #1, outcomes were compared between bare-metal stents and contemporary CABG; in W
MACCE  major adverse cardiac and cerebrovascular events; MACE  major adverse card
evascularization; other abbreviations as in Table 1.ignificantly higher with stenting than with CABG for 0atients having 2-vessel (HR: 1.739; 95% CI: 1.171 to
.582; p  0.006) or 3-vessel (HR: 1.493; 95% CI: 1.096
o 2.035; p  0.011) disease in the overall patient
opulation. When the patients were separated into
aves #1 and #2, the HRs of MACCE were significantly
igher with stenting for patients with isolated ULMCA
HR: 3.113; 95% CI: 1.069 to 9.062; p  0.037) and
-vessel disease (HR: 2.152; 95% CI: 1.309 to 4.456; p 
.039) in Wave #1, and those with 2-vessel disease (HR:
.384; 95% CI: 1.329 to 4.277; p  0.004) in Wave #2.
nteractions of extra-ULMCA coronary artery involve-
ent with treatment type were not significant in all
ubgroups.
In other Cox models, when the outcomes were adjusted
ith the SYNTAX score and EuroSCORE for 1,580
atients, the HRs of MACCE were still less favorable to
tenting in patients with isolated ULMCA stenosis (HR:
.970; 95% CI: 0.878 to 10.043; p  0.080), those with
-vessel (HR: 1.482; 95% CI: 0.664 to 3.309; p  0.337),
-vessel (HR: 1.667; 95% CI: 0.978 to 2.840; p  0.060),
nd 3-vessel (HR: 1.505; 95% CI: 1.007 to 2.250; p 
t 4 Years
LM With 2 Vessels LM With 3 Vessels
ank
lue Stent CABG
Log-Rank
p Value Stent CABG
Log-Rank
p Value
287 299 273 649
1 5.7 7.8 0.333 10.6 13.3 0.366
8 0.7 0.4 0.538 1.6 1.5 0.879
1 1.1 1.7 0.507 1.5 1.9 0.687
0 7.0 9.5 0.320 12.9 14.7 0.588
4 12.4 4.2 0.001 11.1 2.0 0.001
5 17.9 4.9 0.001 15.7 3.6 0.001
3 23.0 14.2 0.006 25.0 17.6 0.003
70 139 33 199
4 7.2 10.8 0.427 16.3 12.1 0.474
0 1.4 0.8 0.612 0 1.1 0.605
4 1.5 1.5 0.985 0 1.1 0.592
2 8.6 12.2 0.464 16.3 13.1 0.583
6 23.9 5.2 0.001 15.5 2.7 0.001
9 25.5 6.8 0.001 18.6 3.2 0.001
9 29.0 18.7 0.098 31.0 15.6 0.014
217 160 240 450
0 5.1 5.1 0.964 9.9 13.7 0.190
0.5 0 0.390 1.8 1.6 0.919
1 0.9 1.9 0.426 1.7 2.3 0.624
1 6.5 7.0 0.880 12.5 15.2 0.363
8 8.9 3.4 0.032 10.4 1.7 0.001
7 15.6 3.4 0.001 15.2 3.9 0.001
6 21.2 10.3 0.005 24.2 18.5 0.043
, outcomes were compared between drug-eluting stents and contemporary CABG.
nts; MI  myocardial infarction; TLR  target lesion revascularization; TVR  target vesselses a
sel
Log-R
p Va
0.37
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0.88
0.12
0.51
0.03
0.03
0.23
0.65
—
0.34
0.65
0.70
0.24
0.32
ave #2.046) disease. However, with regard to the MACE, the
H
0
(
C
C
c
D
D
s
s
a
f
b
i
S
t
p
i
e
l
U
a
w
p
r
o
r
U
D
o
s
U
d
s
n
4
f
l
S
f
r
s
a
(
s
i
s
i
m
C
d
d
r
s
s
2549JACC Vol. 55, No. 23, 2010 Kim et al.
June 8, 2010:2544–52 Left Main With Multivessel DiseaseRs of stenting were 0.865 (95% CI: 0.519 to 1.443; p 
.579) in isolated left main coronary artery stenosis, 1.037
95% CI: 0.389 to 2.763; p 0.942) in 1-vessel, 0.804 (95%
I: 0.358 to 1.805; p  0.597) in 2-vessel, and 0.865 (95%
I: 0.519 to 1.443; p  0.579) in 3-vessel disease, as
ompared with CABG.
iscussion
espite DES showing feasible outcomes for ULMCA in
everal registries, concerns remain regarding the long-term
afety of DES in high-risk patients with complex coronary
natomies. In particular, for ULMCA disease (18–20), the
requent occurrence of multivessel disease may show greater
enefits with CABG, enabling more complete revascular-
zation than with percutaneous coronary intervention (21).
ubgroup analysis of the SYNTAX trial showed a tendency
oward a higher event rate with DES than with CABG in
atients with multivessel disease, but not in those with
solated ULMCA or 1-vessel disease (13). To date, how-
ver, no study in large numbers of patients has assessed the
ong-term clinical outcomes following revascularization for
LMCA stenosis in patients with extra-ULMCA coronary
rtery disease. Therefore, this study has an advantage, in
hich it specifically addresses this issue in a relatively large
atient population taken from a nation-based registry en-
olling all patients consecutively revascularized with stenting
r CABG for ULMCA disease. Of our patients, 75%
eceiving stents and 94% receiving CABG had extra-
Stent in LM + 3-vessel
Stent in LM + 2-vessel
CABG in LM + 2-vessel
Patients at risk 
CABG in LM + 3-vessel
All p=NS between stent vs. CABG
40
30
20
10
0
Stent in LM + 1-vessel
Stent in Isolated LM
CABG in Isolated LM
CABG in LM + 1-vessel
Cumulative Incidence of 
MACE (%) 
D
Figure 1 Kaplan-Meier Analysis of the 4-Year Cumulative Incide
Following Stenting or CABG Surgery for ULMCA Steno
(Left) Cumulative incidences of major adverse cardiac events including death, Q-w
cardiac and cerebrovascular events including death, Q-wave myocardial infarction,
left main; MACCE  major adverse cardiac and cerebrovascular events; MACE  mLMCA coronary artery disease. TIn contrast to concerns regarding the long-term safety of
ES in patients with complex coronary lesions (18,19,22),
ur results indicate that stenting and CABG for UMLCA
tenosis were of comparable safety, regardless of extra-
LMCA coronary artery disease. The long-term risks of
eath, stroke, or MACE were almost identical following
tenting and CABG in all subgroups stratified by the
umber of diseased vessels. In all subgroups, the observed
-year incidence of MACE was within a narrow range,
rom 7% to 16%. This result is in agreement with the recent
arge randomized ISAR-LEFT-MAIN (Intracoronary
tenting and Angiographic Results: Drug-Eluting Stents
or Unprotected Coronary Left Main Lesions) study or the
egistry of the DELFT (Drug Eluting Stent for Left Main)
tudy, which enrolled ULMCA disease treated with DES
nd showed approximately 10% mortality over 2 years
11,12). Moreover, safety performance of both treatment
trategies was also in agreement with the results of random-
zed studies comparing BMS and CABG, which showed no
ignificant differences in long-term mortality or myocardial
nfarction in patients with multivessel disease (23–27). A
eta-analysis of 4 randomized controlled trials comparing
ABG and BMS found that, for patients with multivessel
isease, the 1-year combined incidences of death, myocar-
ial infarction, or stroke were 9.1% and 8.7%, respectively,
ates that did not differ significantly (27). More recent
tudies also showed that DES and CABG are of comparable
afety in patients with multivessel disease (9,10,13,28,29).
Days
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Days
of Outcomes
tratified by Vascular Disease
yocardial infarction, or stroke. (Right) Cumulative incidences of major adverse
, or target vessel revascularization. CABG  coronary artery bypass graft; LM 
dverse cardiac events; ULMCA  unprotected left main coronary artery.ays
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Left Main With Multivessel Disease June 8, 2010:2544–52-year incidences of death, myocardial infarction, or stroke
ere 7.7% for CABG and 7.6% for stenting (p 0.98) (13).
The safety of ULMCA revascularization was further
videnced by analysis of multivariable Cox models within
he CABG or stent group. The risk of safety outcomes was
ot associated with the number of extra-ULMCA coronary
rtery involvement. In both unadjusted and adjusted analy-
es, the HRs of MACE in patients with extra-ULMCA
oronary artery disease, even those having 3-vessel disease,
id not differ significantly from the HRs in patients with
solated ULMCA stenosis, either in the stent or CABG
roup. This finding, combined with the results of our
revious study, showing that a EuroSCORE integrating
linical risk profiles was the strongest predictor of long-term
ortality or myocardial infarction (15), indicates that clin-
cal factors other than angiographic extent of extra-
LMCA coronary artery disease may contribute more
ignificantly to long-term clinical outcomes.
Our results suggest that a major finding of the MAIN-
OMPARE study, showing a greater tendency of TVR
0 . 1 1 1 0
A d j u s t e d  H a z a r d  R a t i o  ( 9 5 %  C I )
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Figure 2 Impact of Vascular Disease on Outcomes Following
Stenting or CABG Surgery for ULMCA Stenosis
Hazard ratios and confidence intervals of (top) death; (middle) MACE including
death, Q-wave myocardial infarction, or stroke; and (bottom) MACCE including
death, Q-wave myocardial infarction, stroke, or target vessel revascularization
in patients stratified by the number of vessel disease (VD). Abbreviations as in
Figure 1.ith stenting than with CABG, may be broadly applicableo subgroups of patients with or without extra-ULMCA
oronary artery stenosis (5). Particularly, for patients with 2-
r 3-vessel disease, the risk of MACCE was approximately
0% higher with stenting than with CABG, driven by the
ncreased TVR rate. Even in patients with isolated
LMCA or 1-vessel disease, CABG showed lower risks,
lthough the differences were not statistically significant due
o the small sample distribution. This finding is in agree-
ent with the previous randomized or registry studies for
atients with multivessel disease, which reported a higher
ncidence of TVR following percutaneous coronary inter-
ention than CABG (24–27,30). Stenting with DES was
lso associated with a higher incidence of TVR than CABG
or multivessel disease (9,10,13,30). In fact, in our unad-
usted and adjusted analyses, the number of diseased vessels
id not significantly influence the long-term outcomes with
se of CABG. However, in the stent group, there was a
endency toward an increased crude rate of MACE or
ACCE for patients with 3-vessel disease than those with
0 .1 1 1 0
A d ju s te d  H a z a rd  R a t io  (9 5 %  C I )
0 .1 1 1 0
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Interaction p=0.271
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Figure 3
Outcomes of Stenting Compared
With CABG Surgery for LM Stenosis
in Patients Stratified by Number of VD
Hazard ratios and confidence intervals of (top) death; (middle) MACE including
death, Q-wave myocardial infarction, or stroke; and (bottom) MACCE including
death, Q-wave myocardial infarction, stroke, or target vessel revascularization.
Abbreviations as in Figures 1 and 2.
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June 8, 2010:2544–52 Left Main With Multivessel Diseasesolated ULMCA or 1-vessel disease. Given this result, our
tudy supports the recent consensus statement that CABG
urgery can be considered as the first-line therapy for
LMCA stenosis before a large randomized trial compar-
ng stenting and CABG for ULMCA stenosis is performed
31). However, in contrast to our study, the left main
ubstudy of the SYNTAX trial suggested that the effect of
hese 2 treatment strategies was dependent on vascular
tenosis (13). For instance, the incidence of MACCE was
ikely to be higher for stenting than CABG in patients with
LMCA plus 2- or 3-vessel disease, but was lower for
tenting in patients with isolated ULMCA or 1-vessel
isease.
The difference between the SYNTAX trial and ours
egarding the impact of extra-ULMCA coronary artery
nvolvement may be explained by several factors. First, in
ontrast to the restricted population in the randomized trial,
ur nation-based registry reflected an overall population
reated in real-world practice. Second, the 1-year follow-up
eriod in the SYNTAX trial may not be sufficient to
ompare the effectiveness of CABG and stenting. Because
he benefit of CABG over medical therapy has been
eported to become apparent after 1 year, longer follow-up
ay be necessary (21). Third, our mandatory practice of
ngiographic follow-up after stenting might increase the
nnecessary need for TVR (32,33). Because angiographic
urveillance is generally recommended after stenting but not
fter CABG, angiographic follow-up was performed in 73%
f the stent group and 15% of the CABG group (34). A
revious angiographic substudy of a randomized trial sug-
ested that angiographic surveillance approximately doubled
he risk of repeat revascularization (33). Moreover, because
evascularization treatment was greatly influenced by the
ractice pattern of country, institution, and operator, a post
oc comparison of TVR across the studies is very difficult.
inally, a lack of information regarding the interaction test
n the SYNTAX trial limits our ability to compare the
esults of the 2 studies (14). We observed no significant
nteraction between treatment type and vascular involve-
ent in the overall study period, as well with BMS or DES.
his analysis indicates that the differences between CABG
nd stenting may be homogenously maintained across all
ubgroups stratified in our study. Nonetheless, it is note-
orthy that the effectiveness gap between the stent and
ABG is gradually decreasing by advancement of stenting
echnique and use of DES. In our analysis, the incidence of
VR was much lower with use of DES as compared with
MS.
tudy limitations. First, although we included a relatively
arge study population based on a national registry, it is still
nderpowered to detect small differences between stenting
nd CABG in multiple comparisons. In fact, the negative
esults with insufficient sample size and event counts may be
isinterpreted due to the unstable estimates of effect,
ncongruous patterns of results across subgroups, inability to
mploy a sufficient number of control variables to removeotential biases, intergroup differences or interactions in
aseline parameters, and underpowered main effects tests
35). Therefore, an impact of important clinical risks, such
s diabetes mellitus, on the differential outcomes between
tenting and CABG could not be adequately assessed. To
valuate the power of observed effect, post-hoc power analysis
ay play a role after completion of study (36). Nevertheless,
iven the exploratory purpose of this substudy, our result may
rovide useful information for further clinical researches. Sec-
nd, despite our multivariable Cox adjustments, observational
nd nonrandomized study design has inherent limitations for
xcluding potential biases. Furthermore, due to the small
ample size and rare event rate in each subgroup, more rigorous
djustments with propensity-score or inverse-probability-of-
reatment weighting could not be tried (37,38). However, any
ias may not be serious, inasmuch as the pattern of significance
as consistently observed in unadjusted and adjusted out-
omes. Third, a lack of full angiographic adjustment may be a
esidual bias in interpreting the outcomes because angiographic
nalysis was performed for 71% of patients. Nonetheless, the
attern of HRs of MACE or MACCE after stenting, as
ompared with CABG, was consistent after adjustments with
ither EuroSCORE or SYNTAX score (15).
onclusions
percutaneous approach with stenting appears to be a safe
lternative to CABG in patients with ULMCA and vascular
isease. The advantage of CABG over percutaneous inter-
ention seems to lie principally in the reduction of repeat
evascularization across the subgroups analyzed in our study.
owever, additional randomized studies, using a sufficient
ample size, are required to provide stronger evidence.
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